<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04784442</url>
  </required_header>
  <id_info>
    <org_study_id>346-102-00001</org_study_id>
    <nct_id>NCT04784442</nct_id>
  </id_info>
  <brief_title>A Dose-finding Trial of ETC-1002(Bempedoic Acid) in Patients With Hypercholesterolemia</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the low-density lipoprotein cholesterol&#xD;
      (LDL-C)-lowering efficacy and safety of ETC-1002(bempedoic acid) 60 mg, 120 mg and 180 mg&#xD;
      versus placebo added to ongoing stable statin therapy or other lipid-modifying therapies in&#xD;
      Japanese patients with hypercholesterolemia treated for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 24, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>•Percent change from baseline to Week 12 in LDL-C</measure>
    <time_frame>Baseline, week12</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">176</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>ETC-1002 180mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ETC-1002 120mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ETC-1002 60mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>180mg of ETC-1002(bempedoic acid)</intervention_name>
    <description>180mg, tablet, once daily, for 12 weeks</description>
    <arm_group_label>ETC-1002 180mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>120mg of ETC-1002(bempedoic acid)</intervention_name>
    <description>120mg, tablet, once daily, for 12 weeks</description>
    <arm_group_label>ETC-1002 120mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>60mg of ETC-1002(bempedoic acid)</intervention_name>
    <description>60mg, tablet, once daily, for 12 weeks</description>
    <arm_group_label>ETC-1002 60mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo, tablet, once daily, for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who have obtained informed consent to all of the&#xD;
             observation/examination/evaluation items specified in the protocol&#xD;
&#xD;
          -  Patients must be on stable statin therapy defined as atorvastatin, pitavastatin,&#xD;
             rosuvastatin, pravastatin, simvastatin, or fluvastatin daily[and other lipid-modifying&#xD;
             therapies(LMTs) if needed] at least 4 weeks(6 weeks for fibrates) prior to screening&#xD;
             and above LDL-C control target. Or Patients for statin intolerant must be on stable&#xD;
             LMT(s) at least 4 weeks prior to screening and above LDL-C control target. Statin&#xD;
             intolerance defined as an inability to tolerate 1 or more statins due to an adverse&#xD;
             safety effect that started or increased during statin therapy and resolved or improved&#xD;
             when statin therapy was discontinued or decreased. Patients on the lowest or under the&#xD;
             dosage of the approved dose of statin or unable to tolerate any statin at any dose&#xD;
             were eligible. Patients could continue taking the lowest or under the dosage of the&#xD;
             approved dose of statin therapy or taking other LMTs throughout the study provided&#xD;
             that it was stable and well tolerated.&#xD;
&#xD;
          -  Fasting mean TG level &lt; 400 mg/dL from measurements at screening&#xD;
&#xD;
          -  Other protocol specific inclusion criteria may apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding or who have a positive pregnancy test (urine)&#xD;
             result at screening or baseline visits&#xD;
&#xD;
          -  Sexually active male subjects or sexually active female subjects of childbearing&#xD;
             potential who do not agree to practice 2 different methods of birth control or to&#xD;
             remain abstinent during the trial and for 30 days after final IMP administration test&#xD;
             (urine) result at screening or baseline visits&#xD;
&#xD;
          -  Patients with homozygous familial hypercholesterolemia (HoFH)&#xD;
&#xD;
          -  Patients with a history or current symptoms of any of the following clinically&#xD;
             significant cardiovascular diseases within 3 months prior to screening or before&#xD;
             baseline visit&#xD;
&#xD;
               -  Myocardial infarction, severe or unstable angina pectoris, coronary angioplasty,&#xD;
                  coronary artery bypass graft, stroke, transient ischemic attack, symptomatic&#xD;
                  carotid artery stenosis, symptomatic peripheral arterial disease, or&#xD;
                  decompensated heart failure&#xD;
&#xD;
               -  Abdominal aortic aneurysm&#xD;
&#xD;
               -  Unexplained syncope or long-QT syndrome, family history of long-QT syndrome, or&#xD;
                  risk factors for Torsade de Pointes, such as persistent hypokalemia or second- or&#xD;
                  third-degree atrioventricular block (except when controlled by medication, etc)&#xD;
&#xD;
          -  Uncontrolled hypertension, defined as follows:&#xD;
&#xD;
               -  Sitting systolic blood pressure after resting 5 minutes of ≥160 mmHg or diastolic&#xD;
                  blood pressure of ≥100 mmHg at screening&#xD;
&#xD;
          -  Patients with uncontrolled and serious hematologic or coagulation disorders or with&#xD;
             Hgb of &lt;10.0 g/dL at screening&#xD;
&#xD;
          -  Patients with type 1 diabetes or uncontrolled type 2 diabetes with hemoglobin A1c&#xD;
             (HbA1c) of ≥9% at screening&#xD;
&#xD;
          -  Patients with uncontrolled hypothyroidism with thyroid-stimulating hormone (TSH) of&#xD;
             &gt;1.5 × ULN at screening&#xD;
&#xD;
          -  Patients with liver disease or dysfunction, including:&#xD;
&#xD;
               -  Positive serology for hepatitis B surface antigen (HBsAg) and/or hepatitis C&#xD;
                  antibodies at screening&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) of ≥3 × ULN&#xD;
                  and/or total bilirubin of ≥2 × ULN&#xD;
&#xD;
          -  Patients with creatine kinase (CK) elevation( &gt;3 × ULN) at screening&#xD;
&#xD;
          -  Patients with renal dysfunction or nephritic syndrome or a history of nephritis and&#xD;
             with estimated glomerular filtration rate (eGFR) of ≤30 mL/min/1.73m2 at screening&#xD;
&#xD;
          -  Other protocol specific inclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takehisa Matsumaru</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Tokyo-Eki Center-Building Clinic</name>
      <address>
        <city>Chuo-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2021</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>: Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be available after marketing approval in global markets, or beginning 1-3 years following article Publication. There is no end date to the availability of the data.</ipd_time_frame>
    <ipd_access_criteria>Otsuka will share data on an Otsuka-owned remotely accessible data sharing platform with Python and R analytical software. Research requests should be directed to clinicaltransparency@Otsuka-us.com.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

